A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer
Latest Information Update: 16 Oct 2025
At a glance
- Drugs VIR 5500 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms AMX-500-001
- Sponsors Amunix; Vir Biotechnology
Most Recent Events
- 24 Sep 2025 Planned number of patients changed from 215 to 390.
- 24 Jul 2025 According to Vir Biotechnology media release, Dose escalation continues for this study of PRO-XTEN™ dual-masked TCEs VIR-5500 (PSMA), with compelling early clinical response signals and promising safety profiles.
- 07 May 2025 According to a Vir Biotechnology media release, company continues to advance through dose escalation aiming to further optimize dosing and efficacy.